Related Experiment Video
Updated: May 8, 2026
10:37
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
Published on: November 15, 2017
[Proteomic analysis for the development of biopharmaceuticals]
1Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan. kamada@nibio.go.jp
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|September 3, 2013
Summary
Discovering effective biomarkers and drug targets is crucial for biopharmaceutical development. A novel antibody proteomics technology enables monoclonal antibody generation from nanogram protein levels, simplifying target identification for diseases like cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Context:
- Biopharmaceuticals offer advanced treatment options for cancer and refractory diseases.
- Identifying suitable biomarkers and drug targets is a critical challenge in biopharmaceutical development.
- Proteomics, particularly the analysis of protein expression, is vital for target discovery.
Purpose:
- To introduce a novel "antibody proteomics technology" for efficient target molecule identification.
- To enable the generation of monoclonal antibodies from minute protein quantities (nanogram level).
- To streamline the development of effective biomarkers and drug targets for biopharmaceutical applications.
Summary:
- Proteomics plays a key role in identifying disease-specific protein targets.
- The presented antibody proteomics technology facilitates monoclonal antibody production using minimal protein amounts.
- This method simplifies the selection and validation of promising biomarkers and drug targets.
Impact:
- Accelerates the drug development pipeline for novel biopharmaceuticals.
- Enhances the precision and efficiency of biomarker and drug target discovery.
- Facilitates the creation of more effective diagnostics and therapeutics for challenging diseases.
